GALLARD SCHLESINGER INDUSTRIES, INC. – Trademark Portfolio
Entity Type: 03
GALLARD SCHLESINGER INDUSTRIES, INC. holds 19 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 12 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ISOLYMPH. The owner is based in CARLE PLACE, NY.
584 MINEOLA AVENUE
CARLE PLACE, NY 11514
Showing of trademarks Trademarks
Trademark Classifications
GALLARD SCHLESINGER INDUSTRIES, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does GALLARD SCHLESINGER INDUSTRIES, INC. have?
GALLARD SCHLESINGER INDUSTRIES, INC. has 19 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 abandoned, 16 cancelled.
What trademark classes does GALLARD SCHLESINGER INDUSTRIES, INC. file in?
GALLARD SCHLESINGER INDUSTRIES, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 35 (Advertising & Business). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are GALLARD SCHLESINGER INDUSTRIES, INC.'s most well-known trademarks?
GALLARD SCHLESINGER INDUSTRIES, INC.'s registered trademark portfolio includes well-known marks such as ISOLYMPH. These are among 1 currently registered trademark in the portfolio.
What is GALLARD SCHLESINGER INDUSTRIES, INC.'s trademark registration success rate?
GALLARD SCHLESINGER INDUSTRIES, INC. has a 5% trademark registration rate, with 1 out of 19 resolved applications resulting in successful registration. Currently, 0 applications are pending review.